Buck Law Firm Atlanta Attorneys The Buck Law Firm
Free Initial Consultation Toll Free 888-594-9958 Local 678-348-6020
Practice Areas

Another drug manufacturer could face products liability claims

Georgia residents who suffer from osteoarthritis know the condition cannot be cured. However, medications are available that can at least help manage the pain associated with this condition. One of those medications is Limbrel, which recently made headlines due to complaints received by the U.S. Food and Drug Administration. Due to the potentially severe health consequences caused by the medication, products liability claims could be filed across the country.

According to reports, the FDA wants the drug's manufacturer, Primus Pharmaceuticals, to recall Limbrel voluntarily due to health concerns for those who take the drug for a prolonged period of time. In fact, in Nov. 2016, the FDA issued a warning for consumers to cease using the medication immediately while the agency conducted its investigation into claims of lung and liver damage associated with taking it. At that time, at least 194 complaints had already reached the agency indicating instances of hypersensitivity pneumonitis and injuries to the liver.

The warning triggered even more complaints about the medication. So far, the FDA has linked adverse health consequences to the drug in 30 of the reports. Primus says that Limbrel is actually a medical food, but the FDA now classifies it as an unapproved drug. Unfortunately, the agency does not have the power to force the company to recall the product. It is hoped that Primus will voluntarily issue a recall as the instances of adverse health events increases.

As for Georgia residents who take Limbrel, they may want to consult with their doctors to stop taking this medication and find a suitable replacement. If injuries have already occurred, they can be reported to the FDA. In addition, the filing of a products liability claim against Primus Pharmaceuticals may help victims recover some restitution for the financial losses and other damages caused by this medication.

Source: beckershospitalreview.com, "FDA urges drugmaker to recall osteoarthritis product following liver and lung injury reports", Alia Paavola, Dec. 6, 2017

No Comments

Leave a comment
Comment Information
Email Our Attorneys